Your browser doesn't support javascript.
loading
Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fcγ Receptors.
Tutt, Alison L; James, Sonya; Laversin, Stéphanie A; Tipton, Thomas R W; Ashton-Key, Margaret; French, Ruth R; Hussain, Khiyam; Vaughan, Andrew T; Dou, Lang; Earley, Alexander; Dahal, Lekh N; Lu, Chen; Dunscombe, Melanie; Chan, H T Claude; Penfold, Christine A; Kim, Jinny H; Potter, Elizabeth A; Mockridge, C Ian; Roghanian, Ali; Oldham, Robert J; Cox, Kerry L; Lim, Sean H; Teige, Ingrid; Frendéus, Bjorn; Glennie, Martin J; Beers, Stephen A; Cragg, Mark S.
Afiliación
  • Tutt AL; Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, Hampshire SO16 6YD, United Kingdom; and.
  • James S; Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, Hampshire SO16 6YD, United Kingdom; and.
  • Laversin SA; Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, Hampshire SO16 6YD, United Kingdom; and.
  • Tipton TR; Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, Hampshire SO16 6YD, United Kingdom; and.
  • Ashton-Key M; Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, Hampshire SO16 6YD, United Kingdom; and.
  • French RR; Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, Hampshire SO16 6YD, United Kingdom; and.
  • Hussain K; Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, Hampshire SO16 6YD, United Kingdom; and.
  • Vaughan AT; Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, Hampshire SO16 6YD, United Kingdom; and.
  • Dou L; Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, Hampshire SO16 6YD, United Kingdom; and.
  • Earley A; Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, Hampshire SO16 6YD, United Kingdom; and.
  • Dahal LN; Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, Hampshire SO16 6YD, United Kingdom; and.
  • Lu C; Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, Hampshire SO16 6YD, United Kingdom; and.
  • Dunscombe M; Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, Hampshire SO16 6YD, United Kingdom; and.
  • Chan HT; Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, Hampshire SO16 6YD, United Kingdom; and.
  • Penfold CA; Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, Hampshire SO16 6YD, United Kingdom; and.
  • Kim JH; Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, Hampshire SO16 6YD, United Kingdom; and.
  • Potter EA; Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, Hampshire SO16 6YD, United Kingdom; and.
  • Mockridge CI; Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, Hampshire SO16 6YD, United Kingdom; and.
  • Roghanian A; Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, Hampshire SO16 6YD, United Kingdom; and.
  • Oldham RJ; Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, Hampshire SO16 6YD, United Kingdom; and.
  • Cox KL; Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, Hampshire SO16 6YD, United Kingdom; and.
  • Lim SH; Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, Hampshire SO16 6YD, United Kingdom; and.
  • Teige I; BioInvent International, 22362 Lund, Sweden.
  • Frendéus B; BioInvent International, 22362 Lund, Sweden.
  • Glennie MJ; Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, Hampshire SO16 6YD, United Kingdom; and.
  • Beers SA; Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, Hampshire SO16 6YD, United Kingdom; and.
  • Cragg MS; Antibody and Vaccine Group, Cancer Sciences Unit, University of Southampton Faculty of Medicine, Southampton General Hospital, Southampton, Hampshire SO16 6YD, United Kingdom; and msc@soton.ac.uk.
J Immunol ; 195(11): 5503-16, 2015 Dec 01.
Article en En | MEDLINE | ID: mdl-26512139
ABSTRACT
FcγRs are key regulators of the immune response, capable of binding to the Fc portion of IgG Abs and manipulating the behavior of numerous cell types. Through a variety of receptors, isoforms, and cellular expression patterns, they are able to fine-tune and direct appropriate responses. Furthermore, they are key determinants of mAb immunotherapy, with mAb isotype and FcγR interaction governing therapeutic efficacy. Critical to understanding the biology of this complex family of receptors are reagents that are robust and highly specific for each receptor. In this study, we describe the development and characterization of mAb panels specific for both mouse and human FcγR for use in flow cytometry, immunofluorescence, and immunocytochemistry. We highlight key differences in expression between the two species and also patterns of expression that will likely impact on immunotherapeutic efficacy and translation of therapeutic agents from mouse to clinic.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Inmunoglobulina G / Receptores de IgG / Anticuerpos Monoclonales Límite: Animals / Humans Idioma: En Revista: J Immunol Año: 2015 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Inmunoglobulina G / Receptores de IgG / Anticuerpos Monoclonales Límite: Animals / Humans Idioma: En Revista: J Immunol Año: 2015 Tipo del documento: Article